Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) announced its quarterly earnings data on Thursday. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.09), MarketWatch Earnings reports.
Shares of NASDAQ DAWN traded up $0.70 during mid-day trading on Friday, reaching $7.65. The company had a trading volume of 461,834 shares, compared to its average volume of 218,898. Day One Biopharmaceuticals has a 52-week low of $6.53 and a 52-week high of $28.70. The firm has a 50 day simple moving average of $10.14 and a two-hundred day simple moving average of $14.62.
A number of institutional investors have recently added to or reduced their stakes in DAWN. Royal Bank of Canada acquired a new position in Day One Biopharmaceuticals during the third quarter valued at approximately $33,000. Morgan Stanley acquired a new position in Day One Biopharmaceuticals during the second quarter valued at approximately $54,000. Citigroup Inc. lifted its position in Day One Biopharmaceuticals by 266.1% during the fourth quarter. Citigroup Inc. now owns 4,682 shares of the company’s stock valued at $79,000 after buying an additional 3,403 shares in the last quarter. Bank of America Corp DE lifted its position in Day One Biopharmaceuticals by 1,074.6% during the fourth quarter. Bank of America Corp DE now owns 5,685 shares of the company’s stock valued at $96,000 after buying an additional 5,201 shares in the last quarter. Finally, American International Group Inc. lifted its position in Day One Biopharmaceuticals by 92.7% during the first quarter. American International Group Inc. now owns 11,294 shares of the company’s stock valued at $112,000 after buying an additional 5,434 shares in the last quarter. Hedge funds and other institutional investors own 79.02% of the company’s stock.
Day One Biopharmaceuticals Company Profile (Get Rating)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
- Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.